Reneo Pharmaceuticals, Inc. (RPHM)
| Market Cap | 58.82M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -70.71M |
| Shares Out | 33.42M |
| EPS (ttm) | -2.18 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 113,037 |
| Open | 1.650 |
| Previous Close | 1.750 |
| Day's Range | 1.650 - 1.770 |
| 52-Week Range | 0.980 - 9.450 |
| Beta | 0.23 |
| Analysts | Buy |
| Price Target | 11.46 (+547.46%) |
| Earnings Date | May 7, 2024 |
About RPHM
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquarte... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for RPHM stock is "Buy." The 12-month stock price forecast is $11.46, which is an increase of 547.46% from the latest price.
News
RENEO PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Reneo Pharmace...
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of Reneo Pharmaceuticals, Inc. - RPHM
NEW YORK , May 13, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securitie...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SQSP, RPHM
NEW YORK , May 13, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches ...
Shareholder Alert: Ademi LLP investigates whether Reneo Pharmaceuticals, Inc. has obtained a Fair Price in its Transaction with OnKure
MILWAUKEE , May 13, 2024 /PRNewswire/ -- Ademi LLP is investigating Reneo (Nasdaq: RPHM) for possible breaches of fiduciary duty and other violations of law in its going private transaction with OnKur...
RPHM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Reneo Pharmaceuticals, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) and OnKure, Inc. is fair to Reneo shareholde...
Reneo Pharmaceuticals and OnKure Announce Proposed Merger
Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing OnKure's portfolio of novel precision medicines in oncology
Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results
IRVINE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for pat...
Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update
IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for p...
Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
The STRIDE study did not meet its primary or secondary efficacy endpoint The company to suspend mavodelpar development and implement a workforce reduction IRVINE, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE...
Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results
Topline data results from the pivotal STRIDE study are expected in December 2023 Topline data results from the pivotal STRIDE study are expected in December 2023
Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences
IRVINE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for ...
Reneo Pharmaceuticals Announces Poster Presentation at Upcoming Scientific Meetings
IRVINE, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for ...
Reneo Pharmaceuticals Announces Last Patient Last Visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
Topline data results from the STRIDE study are expected in December 2023 Topline data results from the STRIDE study are expected in December 2023
Reneo Pharmaceuticals to Participate in the Jefferies Biotech CNS/Neuro Summit
IRVINE, Calif., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for ...
Reneo Pharmaceuticals Reports Second Quarter 2023 Financial Results
Topline results of the STRIDE study, the pivotal mavodelpar clinical trial in adult patients with primary mitochondrial myopathies (PMM) due to mitochondrial DNA (mtDNA) defects, anticipated in 4Q23 T...
Reneo Pharmaceuticals to Participate in SVB Securities Therapeutics Forum
IRVINE, Calif., June 30, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for ...
Reneo Pharmaceuticals Added to Russell 2000® and Russell 3000® Indices
IRVINE, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for ...
Reneo Pharmaceuticals Announces Presentation and Posters at Mitochondrial Medicine Symposium 2023
IRVINE, Calif., June 15, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for ...
Update -- Reneo Pharmaceuticals to Participate at the Jefferies Healthcare Conference
IRVINE, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for p...
Reneo Pharmaceuticals Reports First Quarter 2023 Financial Results
IRVINE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for p...
Reneo Announces Pricing of Public Offering of Common Stock
IRVINE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Reneo) (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapi...
Reneo Pharmaceuticals Announces Proposed Public Offering of Common Stock
IRVINE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Reneo) (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapi...
Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
IRVINE, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for...
Reneo Pharmaceuticals Achieves Target Enrollment in the Pivotal STRIDE Study of Mavodelpar (REN001) in Primary Mitochondrial Myopathies
Topline data from the STRIDE study expected in the fourth quarter of 2023 Topline data from the STRIDE study expected in the fourth quarter of 2023
Reneo Pharmaceuticals to Participate in SVB Securities Global Biopharma Conference
IRVINE, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for ...